See the DrugPatentWatch profile for trastuzumab

Trastuzumab emtansine, also known by the brand name Kadcyla, is a medication used for the treatment of HER2-positive breast cancer. To determine the patent expiry of trastuzumab emtansine, we will analyze the provided sources.

According to the information from DrugPatentWatch, the patent for trastuzumab emtansine expired on February 3, 2023 [1]. This suggests that generic versions of the drug may become available after this date.

Furthermore, the article from the National Center for Biotechnology Information (NCBI) provides insights into the regulatory aspects of trastuzumab emtansine and its biosimilars. It mentions that trastuzumab emtansine has been approved as a biosimilar in India under the brand name Ujvira [2]. This suggests that the patent for trastuzumab emtansine has expired in India, allowing for the introduction of biosimilar versions of the drug.

In summary, based on the provided sources, the patent for trastuzumab emtansine expired on February 3, 2023 [1]. However, it is important to note that patent laws can vary between countries, so the expiry date may differ depending on the jurisdiction.

Sources:
[1] DrugPatentWatch: Trastuzumab emtansine - https://www.drugpatentwatch.com/p/biologics/ingredient/trastuzumab
[2] National Center for Biotechnology Information (NCBI): Biosimilars in oncology: from development to clinical practice - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465746/